Severe acute respiratory syndrome coronavirus 2 Delta variant (B.1.617.2) (B.1.617.2)

The SARS-CoV-2 Delta variant, also known as lineage B.1.617.2, is a variant of concern that was first identified in India in late 2020 (WHO, 2021). It is characterized by a specific constellation of mutations in the Spike protein, including L452R, T478K, and P681R, which facilitate increased binding affinity to the human angiotensin-converting enzyme 2 (ACE2) receptor and more efficient proteolytic processing (Nature, 2021). These molecular changes result in significantly higher transmissibility and higher viral loads compared to the ancestral strain and the Alpha variant (CDC, 2021). While the Delta variant demonstrated some degree of immune evasion, particularly against certain monoclonal antibodies, it remained a primary target for small-molecule antivirals such as Remdesivir and Nirmatrelvir (NIH, 2023). The variant's impact on public health was profound, leading to global surges in COVID-19 cases and hospitalizations before the emergence of the Omicron variant. Understanding the Delta variant's structure is essential for evaluating the efficacy of existing therapeutics and designing next-generation vaccines (Science, 2021).

Other names

B.1.617.2VOC-21APR-02G/452R.V3SARS-CoV-2 Delta

Therapeutic agents interact with the Delta variant by targeting its structural and non-structural proteins; monoclonal antibodies bind the Spike protein to block ACE2 interaction, while small-molecule antivirals inhibit the RNA-dependent RNA polymerase (RdRp) or the 3C-like protease (Mpro) to halt the viral life cycle (NIH, 2023).